- Y864
- +852 3400 8608
- cesar.wong@polyu.edu.hk
ORCID ID
SCOPUS IDResearch Overview
To develop biomarkers with diagnostic, prognostic and therapeutic significance for Asian common cancers such as colorectal cancer, cervical cancer, nasopharyngeal cancer and their pre-malignant states. To develop novel non-invasive molecular and immunocytochemical tests for clinical applications.
Education and Academic Qualifications
- Bachelor of Applied Science (Medical Laboratory Science), Charles Sturt University
- Master of Applied Science (Medical Laboratory Science), Charles Sturt University
- Doctor of Philosophy in Biology, Hong Kong University of Science and Technology
Professional Qualifications
- Member of Australian Institute of Medical Scientists
- Founding Fellow of The Royal College of Pathologists of Australasia
- Fellow of Hong Kong Society for Molecular Diagnostic Sciences
Achievements
- Inventor of a United States Patent – Plasma or serum marker and process for detection of cancer (Patent no: US7,811,752 B2)
- Inventor of a China Patent, 7-9-2005 - Plasma or serum marker and process for detection of cancer (Patent no: CN1665830)
- Inventor of a provisional United States Patent, 22-8-2014 - A microdevice for continuous sorting of particles and the method of fabricating the same
- Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Li MJW, Wong YKE, Pei XM, Wong SCC. An Update on COVID-19 Pandemic: The Epidemiology, Pathogenesis, Prevention and Treatment strategies. Expert Rev Anti Infect Ther 2020; doi:10.1080/14787210.2021.1863146. (2021 Impact factor: 5.091)
- Wu SYW, Yau HS, Yu MY, Tsang HF (Chan LWC, Cho WCS, Yu ACS, Yim AKY, Li MJW, Wong YKE, Pei XM, Wong SCC. The Diagnostic Methods in the COVID-19 Pandemic, Today and in the Future. Expert Rev Mol Diagn 2020; doi:10.1080/14737159.2020.1816171. (2021 Impact factor: 5.67)
- Chu YL, Li H, Ng PLA, Kong ST, Zhang H, Lin YH, Tai WCS, Yu ACS, Yim AKY, Tsang HF, Cho WCS, Wong SCC. The potential of circulating exosomal RNA biomarkers in cancer. Expert review in Molecular Diagnostics 2020; doi:10.1080/14737159.2020.1745064. (2021 Impact factor5.67)
- Tsang HF , Yu ACS, Wong HT, Leung WMS, Chiou J, Wong YKE, Yim AKY, Tsang DNC, Tsang AK, Wong WT, Wong SCC. Whole genome amplicon sequencing and phylogenetic analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from lineage B.1.36.27 isolated in Hong Kong. Expert Rev Mol Diagn. 2021 Dec 8. doi: 10.1080/14737159.2022.2015330. Epub ahead of print. PMID: 34878349. (2021 Impact factor: 5.67)
- Leung HY, Yeung MHY, Leung WT, Wong KH, Tang WY, Cho WCS, Wong HT, Tsang HF, Wong YKE, Pei XM, Cheng HYL, Chan AKC, Wong SCC. The current and future applications of in situ hybridization technologies in anatomical pathology. Expert Rev Mol Diagn. 2021 Nov 26:1-14. doi: 10.1080/14737159.2022.2007076. Epub ahead of print. PMID: 34779317. (2021 Impact factor: 5.67)
- Ma BB, King AD, Leung L, Wang K, Poon A, Ho WM, Mo F, Chan CM, Chan AT, Wong SC. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer - a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann Oncol, 28(7):1576-1581, 2017. (Impact factor: 51.769; Rank 9/230 in Oncology, Top 5%)
- Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, King A, Chan SL, Leung SF, Kam MK, Yu BK, Zee B, Chan AT. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol, 20(11):1854-1859, 2009. (Impact factor: 51.769; Rank 9/230 in Oncology, Top 5%)
- Wong SC, Chan CM, Ma BB, Hui EP, Ng SS, Lai PB, Cheung MT, Lo ES, Chan AK, Au TC, Lam MY, Chan AT. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res, 15(3):1005-1012, 2009. (Impact factor: 13.801; Rank 16/230 in Oncology, Top 10%)
- Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res, 10(4):1401-1408, 2004. (Impact factor: 13.801; Rank 16/230 in Oncology, Top 10%)
- Wong SC, Lo ES, Cheung MT, Ng EK, Tse CW, Lai PB, Lee KC, Lo YM. Quantification of plasma b-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res, 10(5): 1613-1617, 2004. (Impact factor: 13.801; Rank 16/230 in Oncology, Top 10%)
- Wong SC, Chan CM. Development of a novel tissue-specific method to detect cytokeratin 20 positive - circulating tumor cells in metastatic colorectal cancer. Biotechnology in Hong Kong, Volume 3, Chapter 1
